Pradaxa Increases GI Bleeding But Not Heart Attack Risk, Medicare Data Show
This article was originally published in The Pink Sheet Daily
Executive Summary
Higher incidence of gastrointestinal bleeding among the Medicare population contrasts with findings from an earlier Mini-Sentinel study of dabigatran and bleeding, but FDA said the disparity in results may reflect the age differences in the populations examined.
You may also be interested in...
Pradaxa Bleeding Risk Gets Deeper FDA Scrutiny In Mini-Sentinel Project
A 2012 Sentinel study didn’t find any problems, but FDA wants a closer look now that the dataset has grown.
FDA Chalks Up Pradaxa Safety Scare To “Stimulated Reporting”
In a New England Journal of Medicine editorial, FDA officials stress value and safety of Boehringer Ingelheim’s novel anticoagulant Pradaxa, which is struggling amid highly publicized reports of bleeding.
Mini Sentinel Alleviates FDA Concern Over Pradaxa Bleeding Issue
Data from the pilot program a “driving factor” in the agency’s decision against changing its recommendations for the blood thinner following reports of increased serious bleeding events.